JP2019530728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530728A5 JP2019530728A5 JP2019520627A JP2019520627A JP2019530728A5 JP 2019530728 A5 JP2019530728 A5 JP 2019530728A5 JP 2019520627 A JP2019520627 A JP 2019520627A JP 2019520627 A JP2019520627 A JP 2019520627A JP 2019530728 A5 JP2019530728 A5 JP 2019530728A5
- Authority
- JP
- Japan
- Prior art keywords
- recipient
- transplantation
- antibody
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002054 transplantation Methods 0.000 claims description 91
- 239000000427 antigen Substances 0.000 claims description 81
- 102000036639 antigens Human genes 0.000 claims description 81
- 108091007433 antigens Proteins 0.000 claims description 81
- 239000012634 fragment Substances 0.000 claims description 81
- 238000002560 therapeutic procedure Methods 0.000 claims description 26
- 238000000586 desensitisation Methods 0.000 claims description 20
- 230000004083 survival effect Effects 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 11
- 230000001154 acute effect Effects 0.000 claims description 9
- 238000001574 biopsy Methods 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 9
- 230000000877 morphologic effect Effects 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 230000010410 reperfusion Effects 0.000 claims description 9
- 231100000915 pathological change Toxicity 0.000 claims description 7
- 230000036285 pathological change Effects 0.000 claims description 7
- 230000000451 tissue damage Effects 0.000 claims description 7
- 231100000827 tissue damage Toxicity 0.000 claims description 7
- 230000003907 kidney function Effects 0.000 claims description 6
- 230000036470 plasma concentration Effects 0.000 claims description 6
- 238000002616 plasmapheresis Methods 0.000 claims description 6
- 238000011316 allogeneic transplantation Methods 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 206010048748 Graft loss Diseases 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 229960002224 eculizumab Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000002642 intravenous therapy Methods 0.000 claims description 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 3
- 230000004768 organ dysfunction Effects 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000011272 standard treatment Methods 0.000 claims description 3
- 229960001967 tacrolimus Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 70
- 230000007170 pathology Effects 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 103
- 210000003734 kidney Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022020361A JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407167P | 2016-10-12 | 2016-10-12 | |
| US62/407,167 | 2016-10-12 | ||
| PCT/US2017/056268 WO2018071624A1 (en) | 2016-10-12 | 2017-10-12 | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020361A Division JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530728A JP2019530728A (ja) | 2019-10-24 |
| JP2019530728A5 true JP2019530728A5 (enExample) | 2020-11-12 |
| JP7256741B2 JP7256741B2 (ja) | 2023-04-12 |
Family
ID=60320981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520627A Active JP7256741B2 (ja) | 2016-10-12 | 2017-10-12 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
| JP2022020361A Pending JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020361A Pending JP2022051954A (ja) | 2016-10-12 | 2022-02-14 | 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190276524A1 (enExample) |
| EP (1) | EP3526250A1 (enExample) |
| JP (2) | JP7256741B2 (enExample) |
| WO (1) | WO2018071624A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| ES2888904T3 (es) | 2016-10-19 | 2022-01-10 | Alexion Pharma Inc | Un método de cuantificación de C5a sin unir en una muestra |
| WO2018195034A1 (en) * | 2017-04-19 | 2018-10-25 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| ES2965486T3 (es) | 2017-07-27 | 2024-04-15 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-C5 de alta concentración |
| KR20200070355A (ko) | 2017-10-26 | 2020-06-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| ES2996257T3 (en) | 2018-05-31 | 2025-02-12 | Alexion Pharma Inc | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| WO2020006266A1 (en) | 2018-06-28 | 2020-01-02 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| EP2318048B1 (en) | 2008-07-21 | 2019-05-29 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EP3463460A1 (en) * | 2016-06-07 | 2019-04-10 | Novartis AG | An anti-c5 antibody dosing regimen |
-
2017
- 2017-10-12 US US16/340,453 patent/US20190276524A1/en not_active Abandoned
- 2017-10-12 EP EP17797792.3A patent/EP3526250A1/en not_active Ceased
- 2017-10-12 JP JP2019520627A patent/JP7256741B2/ja active Active
- 2017-10-12 WO PCT/US2017/056268 patent/WO2018071624A1/en not_active Ceased
-
2022
- 2022-02-14 JP JP2022020361A patent/JP2022051954A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530728A5 (enExample) | ||
| US10647770B2 (en) | Therapeutic agent for autoimmune diseases comprising PD-1 agonist | |
| EP2430051B1 (en) | Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases | |
| CN1344275A (zh) | 用淀粉样蛋白抗体除去淀粉样蛋白的方法 | |
| JP2011006449A (ja) | 中間および高グレードの非ホジキンリンパ腫の抗−ｃｄ２０抗体による治療 | |
| FI3556774T3 (fi) | Anti-cd40-vasta-aineita ja niiden käyttötapoja | |
| JP5688734B2 (ja) | 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤 | |
| JP2016531910A (ja) | 移植前の臓器への補体阻害剤の投与による移植拒絶の処置 | |
| JP2025106512A (ja) | 調節性ｔ細胞及びその使用 | |
| Balfour et al. | Use of rituximab to decrease panel-reactive antibodies | |
| JP2014505056A5 (enExample) | ||
| Grellier et al. | Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation | |
| WO2014020922A1 (ja) | 移植片対宿主病などの造血幹細胞移植に伴う疾患を治療することのできる抗体およびその機能断片並びにこれらを含んでなる医薬組成物 | |
| CA1328808C (fr) | Agent actif et medicament en contenant destines a prevenir ou a combattre le rejet de greffe d'organe chez l'homme | |
| JP2021514368A (ja) | Ａｌｌｏ−ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ−ＣＳＦまたはＧＭ−ＣＳＦ受容体のリガンド | |
| JP6942356B2 (ja) | 制御性ｔ細胞の活性化剤及びその使用 | |
| Yasuda et al. | The changes in treatment strategies in ABOi living donor liver transplantation for acute liver failure | |
| KR101694554B1 (ko) | 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물 | |
| JPWO2020178638A5 (enExample) | ||
| US20230073248A1 (en) | Compositions and methods for inducing immune tolerance in transplantation recipients | |
| Amante et al. | Management of highly sensitized patients: capitol medical center experience | |
| AU2005211669C1 (en) | Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
| Singh et al. | Plasmapheresis vs Immunoadsorption vs Combined Plasmapheresis and Immunoadsorption Therapy: A Comparative Analysis of Desensitization Efficacy in ABO Incompatible Renal Transplant with High Baseline Titer | |
| JPWO2023036745A5 (enExample) | ||
| Gupta et al. | Management of steroid-resistant acute rejection in renal transplantation |